How Glycosylation Is Shaping Cancer Biomarker Discovery

• September 2, 2026

Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

• by Manas Ranjan Sahu, Venu Akkanapally, Partha Sarathi Dasgupta, Sujit Basu

• September 2, 2026

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

• by Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan-Birsoy, Gary A. Ulaner, Michael Walsh, Mariko Yabe, Kseniya Petrova-Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa-María López, Jaume Mora, Julien Haroche, Jean-Francois Emile, Olivier Decaux, Frederic Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel-Wahab

• September 1, 2026

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

• by Elizabeth Cifers, MBA, MSW, CHC, CPC

• September 1, 2026

• 4 min